Gert Caspritz, Ph.D.
Dr. Caspritz has been a member of the board since 1999, and served as our Chairman from July 2002 until December 2004. Dr, Caspritz has been a general partner of TVM Capital , or "TVM," and an Investment Manager in the healthcare and Life Sciences group of TVM since June of 1999. Prior to that, Dr.Caspritz held various positions with Hoechst AG. Most recently he was Vice President, New Technologies Licensing at Hoechst Marion Roussel, the pharmaceutical subsidiary of Hoechst, where he had primary global responsibility for identifying business opportunities in the areas of biotechnology, enabling technologies and early-stage products in both the biotech industry and academia. Additionally, he supervised HMR's various venture capital investments and was a member of their strategy teams for oncology and bone diseases and the oncology opportunity review team. Dr. Caspritz was previously Assistant to the Head of Hoechst's worldwide pharmaceutical research and established or led a number of immuno and neuropharmacology laboratories as well as a drug diiscovery group. Dr. Caspritz received degrees in Biology and Microbiology from the University of Mainz, where he wrote his doctoral thesis.